Merus (NASDAQ:MRUS) Given “Buy” Rating at Guggenheim

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating reiterated by Guggenheim in a report released on Wednesday,Benzinga reports.

Several other equities analysts also recently weighed in on the company. Citigroup lifted their target price on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $85.00 price target on shares of Merus in a report on Monday, December 2nd. Needham & Company LLC reissued a “buy” rating and set a $85.00 price target on shares of Merus in a report on Monday, December 9th. The Goldman Sachs Group initiated coverage on Merus in a report on Thursday, November 21st. They set a “buy” rating and a $73.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on Merus in a report on Friday, February 7th. They set an “overweight” rating and a $91.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $86.08.

Merus Trading Down 0.2 %

NASDAQ MRUS traded down $0.10 on Wednesday, hitting $40.02. 10,849 shares of the company traded hands, compared to its average volume of 582,022. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -10.13 and a beta of 1.11. The business’s 50 day moving average price is $41.94 and its 200-day moving average price is $47.52. Merus has a 52-week low of $37.77 and a 52-week high of $61.61.

Institutional Investors Weigh In On Merus

Large investors have recently made changes to their positions in the company. Avior Wealth Management LLC purchased a new stake in Merus during the fourth quarter valued at approximately $76,000. nVerses Capital LLC raised its position in Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the period. US Bancorp DE purchased a new stake in Merus during the third quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. raised its position in Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the period. Finally, MML Investors Services LLC purchased a new stake in Merus during the third quarter valued at approximately $206,000. 96.14% of the stock is owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.